Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.

Autor: Motoko Ida1 motoko.ida@astellas.com, Akito Nishida2, Hiraku Akiho3, Yoshihiro Nakashima4, Kei Matsueda5, Shin Fukudo6
Zdroj: BioPsychoSocial Medicine. 3/16/2017, Vol. 11, p1-10. 10p.
Databáze: Academic Search Ultimate